Publications
36
Citations
489
Est. group size
~6
Recurring co-author estimate
Active years
39
Publishing since 1988
Typically publishes in teams of ~8 · 7% small-team papers (≤3 authors) · across 22 venues
- VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia
Blood Vessels Thrombosis & Hemostasis · 2026
- PD35-04 TARGETED DEGRADATION OF AURORA KINASE A BY NOVEL COMPOUND SP-02-067 ALTERS IMMUNE CHECKPOINT EXPRESSION IN PROSTATE CANCER
The Journal of Urology · 2025
- MP32-18 INTERACTION AND IMPACT OF CYCLIN-DEPENDENT KINASE 12 AND PROTEIN KINASE D1 IN PROSTATE CANCER
The Journal of Urology · 2025
- Abstract 6349: Degradation of Aurora Kinase A, Alters Immune Checkpoint Expressions in Prostate Cancer
Cancer Research · 2025
- EXTH-109. Overexpressing glucose transporters to enhance CAR-T cell metabolic programming to treat glioblastoma
Neuro-Oncology · 2025
- Abstract 4134384: Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis
Circulation · 2024
- SOTAGLIFLOZIN, A FIRST-IN-CLASS SGLT1/2 INHIBITOR, INHIBITS CLOTTING POTENTIAL IN THE VESSEL VIA INHIBITION OF PLATELET ACTIVATION, INTEGRIN ACTIVATION, AND AGGREGATION IN HUMAN PLATELETS
Journal of the American College of Cardiology · 2024
- Antiplatelet strategies: past, present, and future
Journal of Thrombosis and Haemostasis · 2023
- The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
Blood · 2023
- Fatty acids negatively regulate platelet function through formation of noncanonical 15‐lipoxygenase‐derived eicosanoids
Pharmacology Research & Perspectives · 2023
- CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING
Journal of the American College of Cardiology · 2023
- 423 An omega-6-derived eicosanoid negatively regulates platelet reactivity of cardiovascular patients at increased risk for thrombosis
Journal of Clinical and Translational Science · 2023
- Abstract 122: The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor
Arteriosclerosis Thrombosis and Vascular Biology · 2023
- OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis
Research and Practice in Thrombosis and Haemostasis · 2023
- Eicosanoids in inflammation in the blood and the vessel
Frontiers in Pharmacology · 2022
- Journal of Thrombosis and Haemostasis×2
- Biochemistry×2
- Arteriosclerosis Thrombosis and Vascular Biology×2
- Journal of Clinical and Translational Science×2
- Journal of the American College of Cardiology×2
- Michael J. Yaeger
Nursing · The Ohio State University
- Kymberly M. Gowdy
Nursing · The Ohio State University
- Arjun Pitchai
Nursing · Purdue University West Lafayette
- Amber Jannasch
Nursing · Purdue University West Lafayette
- Austin Angelotti
Nursing · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile